PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $804,031 | -22.9% | 26,207 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $1,042,261 | +1.0% | 26,011 | +2.8% | 0.00% | 0.0% |
| Q1 2023 | $1,032,411 | -86.7% | 25,298 | -87.4% | 0.00% | -90.9% |
| Q4 2022 | $7,777,791 | -53.9% | 201,445 | -36.5% | 0.01% | -54.2% |
| Q3 2022 | $16,866,867 | +197.2% | 317,106 | +225.7% | 0.02% | +71.4% |
| Q2 2022 | $5,676,000 | -77.7% | 97,359 | -70.7% | 0.01% | -73.6% |
| Q1 2022 | $25,397,000 | +1380.9% | 332,768 | +1067.5% | 0.05% | +1666.7% |
| Q4 2021 | $1,715,000 | +0.1% | 28,502 | -6.8% | 0.00% | 0.0% |
| Q3 2021 | $1,713,000 | -7.8% | 30,587 | -0.1% | 0.00% | -25.0% |
| Q2 2021 | $1,857,000 | -17.8% | 30,610 | -5.0% | 0.00% | -20.0% |
| Q1 2021 | $2,258,000 | +18.9% | 32,214 | +1.5% | 0.01% | +25.0% |
| Q4 2020 | $1,899,000 | +28.6% | 31,729 | +29.2% | 0.00% | +33.3% |
| Q3 2020 | $1,477,000 | +13.6% | 24,561 | -0.8% | 0.00% | 0.0% |
| Q2 2020 | $1,300,000 | +26.2% | 24,771 | -19.4% | 0.00% | 0.0% |
| Q1 2020 | $1,030,000 | +15.3% | 30,715 | +55.8% | 0.00% | +50.0% |
| Q4 2019 | $893,000 | +45.4% | 19,715 | +22.3% | 0.00% | +100.0% |
| Q3 2019 | $614,000 | -12.4% | 16,125 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $701,000 | +12.7% | 16,125 | -1.3% | 0.00% | +100.0% |
| Q1 2019 | $622,000 | -13.5% | 16,343 | -2.2% | 0.00% | -50.0% |
| Q4 2018 | $719,000 | -9.7% | 16,710 | +3.2% | 0.00% | 0.0% |
| Q3 2018 | $796,000 | +51.9% | 16,190 | -1.1% | 0.00% | +100.0% |
| Q2 2018 | $524,000 | -4.2% | 16,365 | -6.8% | 0.00% | 0.0% |
| Q1 2018 | $547,000 | -98.0% | 17,555 | -97.0% | 0.00% | -98.2% |
| Q4 2017 | $26,863,000 | +21.0% | 588,447 | -0.4% | 0.06% | +16.7% |
| Q3 2017 | $22,193,000 | -0.1% | 590,995 | +26.9% | 0.05% | -4.0% |
| Q2 2017 | $22,221,000 | +9.6% | 465,839 | +4.8% | 0.05% | +8.7% |
| Q1 2017 | $20,274,000 | +16.3% | 444,608 | -17.6% | 0.05% | +9.5% |
| Q4 2016 | $17,430,000 | +44.7% | 539,641 | +53.3% | 0.04% | +82.6% |
| Q3 2016 | $12,045,000 | -2.4% | 351,978 | -3.8% | 0.02% | -23.3% |
| Q2 2016 | $12,336,000 | -14.4% | 365,728 | +34.4% | 0.03% | -16.7% |
| Q1 2016 | $14,419,000 | -41.8% | 272,165 | -15.6% | 0.04% | -40.0% |
| Q4 2015 | $24,766,000 | +64.2% | 322,515 | -12.1% | 0.06% | +57.9% |
| Q3 2015 | $15,083,000 | -26.3% | 366,965 | +26.9% | 0.04% | -19.1% |
| Q2 2015 | $20,455,000 | +18.4% | 289,240 | +48.7% | 0.05% | +23.7% |
| Q1 2015 | $17,282,000 | -32.4% | 194,495 | -32.6% | 0.04% | -33.3% |
| Q4 2014 | $25,579,000 | +79.8% | 288,504 | +96.5% | 0.06% | +78.1% |
| Q3 2014 | $14,228,000 | +35.1% | 146,800 | +28.1% | 0.03% | +33.3% |
| Q2 2014 | $10,530,000 | +841.9% | 114,630 | +617.8% | 0.02% | +700.0% |
| Q1 2014 | $1,118,000 | +21.8% | 15,969 | 0.0% | 0.00% | +50.0% |
| Q4 2013 | $918,000 | +19.5% | 15,969 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $768,000 | +65.9% | 15,969 | 0.0% | 0.00% | +100.0% |
| Q2 2013 | $463,000 | – | 15,969 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |